Human Papillomavirus

The FDA has expanded the age ranges of individuals who may receive the human papillomavirus 9-valent vaccine.

A recent public health goal set by the American Cancer Society aims to have 80% of adolescents vaccinated against HPV by 2026. But is that achievable?

The authors of a new study aimed to estimate the rate of human papillomavirus vaccine completion among women of various races and ethnicities.

Using private insurance claims data, researchers sought to identify predictors of vaccine follow-through among US individuals who initiated the 3-dose human papillomavirus vaccine series. Trends in vaccine...

Human papillomavirus is known to be associated with an increased risk for cervical precancer and cancer. In a new study, researchers aimed to investigate the benefits and harms of prophylactic HPV...

In a recent study, researchers compared the prevalence, incidence, and clearance of human papillomavirus in men who have sex with men, with men who have sex with women.

Using 10 years of data, researchers assessed the efficacy and safety of the HPV vaccine among pre-adolescents and adolescents.

Following the implementation of an extensive HPV vaccination program, researchers sought to examine rates of a rare, difficult-to-treat respiratory disease over a 5-year period.

More than 90% of HPV-associated cancers can potentially be prevented with the HPV vaccine. However, more information is needed on how demographic characteristics affect relative 5-year survival.

Because Hispanics are disproportionally affected by the HIV epidemic and by infection‐related cancers, researchers compared whether incidence rates for HPV‐related cancers and survival differed between...